Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Loteprednol Etabonate Gel 0.38% in Healthy Subjects
NCT03098953Phase 1Completed
- Sponsor
- Bausch + Lomb
- Start
- Apr 2017
- Primary completion
- May 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of loteprednol etabonate in post-operative inflammation and postoperative pain, sponsored by Bausch + Lomb. Primary endpoint: Pharmacokinetic Analysis at Day 15. Started Apr 2017; status: completed.
02
Drugs
loteprednol etabonate
03
Conditions
post-operative inflammationpostoperative pain
Beyond the preview
Go deeper on NCT03098953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03098953.